Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY2605541

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2014
Highly Cited
2014
To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus. 
Highly Cited
2014
Highly Cited
2014
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541… Expand
Review
2014
Review
2014
There is a clinical rationale for a basal insulin with a predictable action and low inter‐ and intra‐individual variability… Expand
2014
2014
OBJECTIVE To use continuous glucose monitoring (CGM) to evaluate the impact of the novel, long-acting basal insulin analog… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
2014
2014
The basal insulin analogue LY2605541, a PEGylated insulin lispro with prolonged duration of action, was previously shown to be… Expand
2014
2014
The first generation of basal insulin analogs, insulin glargine and detemir, are characterized by a more predictable day-to-day… Expand
  • figure 1
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To compare effects of LY2605541 versus insulin glargine on daily mean blood glucose as part of a basal-bolus regimen… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Highly Cited
2012
Highly Cited
2012
IN BRIEF Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to… Expand
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL). RESEARCH… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2